CBLN3
Cerebellin-3
Also known as: CBLN3_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q6UW01
- Gene
- CBLN3
- Ensembl
- ENSG00000139899
- Chromosome
- 14
- Canonical length
- 205 aa
- Protein class
- Predicted intracellular proteins, Predicted secreted proteins
- Subcellular location
- Nucleoplasm
- Secretome location
- Secreted in brain
OverviewNCBI Gene
Members of the precerebellin family, such as CBLN3, contain a cerebellin motif (see CBLN1; MIM 600432) and a C-terminal C1q signature domain (see MIM 120550) that mediates trimeric assembly of atypical collagen complexes. However, precerebellins do not contain a collagen motif, suggesting that they are not conventional components of the extracellular matrix (Pang et al., 2000 [PubMed 10964938]).[supplied by OMIM, Aug 2009]
Canonical amino-acid sequenceUniProt
205 residues, UniProt reviewed canonical sequence.
>Q6UW01|CBLN3
1 MLGAKPHWLP GPLHSPGLPL VLVLLALGAG WAQEGSEPVL LEGECLVVCE PGRAAAGGPG
61 GAALGEAPPG RVAFAAVRSH HHEPAGETGN GTSGAIYFDQ VLVNEGGGFD RASGSFVAPV
121 RGVYSFRFHV VKVYNRQTVQ VSLMLNTWPV ISAFANDPDV TREAATSSVL LPLDPGDRVS
181 LRLRRGNLLG GWKYSSFSGF LIFPLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CBLN3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.43
- Highest tissue expression
- 366 nTPM
Expression across tissuesHPA
Tissue
- cerebellum: 366 nTPM
- adrenal gland: 16 nTPM
- spleen: 13 nTPM
- lymph node: 13 nTPM
- ovary: 9.6 nTPM
- tonsil: 8.6 nTPM
Single-cell type
- brain excitatory neurons: 81 nCPM
- adrenal cortex cells: 10 nCPM
- bergmann glia: 8.7 nCPM
- epididymal principal cells: 7.9 nCPM
- mesothelial cells: 6.7 nCPM
- cardiomyocytes: 5.8 nCPM
Immune cell
- naive B-cell: 0.3 nTPM
- memory B-cell: 0.2 nTPM
- intermediate monocyte: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
Brain region
- cerebellum: 200 nTPM
- pons: 17 nTPM
- cerebral cortex: 13 nTPM
- midbrain: 9 nTPM
- white matter: 8.3 nTPM
- medulla oblongata: 6.7 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.29
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.21
- DepMap mean gene effect
- -0.04
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of CBLN3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CBLN3 as an antibody target. Whether an autoantibody or antibody against CBLN3 could matter depends on whether native CBLN3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CBLN3 is annotated as secreted, so native CBLN3 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label CBLN3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...